Eton Pharmaceuticals, Inc. — Director's Dealing 2018

Nov 16, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eton Pharmaceuticals, Inc. (ETON)
CIK: 0001710340
Period of Report: 2018-11-15

Reporting Person: BRYNJELSEN SEAN (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-15	Common Stock	C	24940	—	Acquired	24940	Indirect
2018-11-15	Common Stock	P	10000	$6.00	Acquired	1010000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-15	Series A Convertible Preferred Stock	$	C	23000	Disposed		Common Stock (24940)	Indirect

Footnotes

F1: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date.